35 results on '"Monneur, Audrey"'
Search Results
2. Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
- Author
-
Bertucci, François, Gonçalves, Anthony, Guille, Arnaud, Adelaïde, José, Garnier, Séverine, Carbuccia, Nadine, Billon, Emilien, Finetti, Pascal, Sfumato, Patrick, Monneur, Audrey, Pécheux, Christophe, Khran, Martin, Brunelle, Serge, Mescam, Lenaïg, Thomassin-Piana, Jeanne, Poizat, Flora, Charafe-Jauffret, Emmanuelle, Turrini, Olivier, Lambaudie, Eric, Provansal, Magali, Extra, Jean-Marc, Madroszyk, Anne, Gilabert, Marine, Sabatier, Renaud, Vicier, Cécile, Mamessier, Emilie, Chabannon, Christian, Pakradouni, Jihane, Viens, Patrice, André, Fabrice, Gravis, Gwenaelle, Popovici, Cornel, Birnbaum, Daniel, and Chaffanet, Max
- Published
- 2021
- Full Text
- View/download PDF
3. Mazabraud Syndrome Associated with McCune-Albright Syndrome: A Case Report and Literature Review
- Author
-
Boudin, Laurys, primary, De Luca, Valeria, additional, Mescam-Mancini, Léna, additional, Niziers, Vincent, additional, Perrot, Delphine, additional, Guiramand, Jerome, additional, Monneur, Audrey, additional, Chagnaud, Christophe, additional, and Bertucci, François, additional
- Published
- 2023
- Full Text
- View/download PDF
4. Reversible rituximab-induced rectal Kaposi’s sarcoma misdiagnosed as ulcerative colitis in a patient with HIV-negative follicular lymphoma
- Author
-
Billon, Emilien, Stoppa, Anne-Marie, Mescam, Lena, Bocci, Massimo, Monneur, Audrey, Perrot, Delphine, and Bertucci, François
- Published
- 2018
- Full Text
- View/download PDF
5. CSPG4 Expression in GIST Is Associated with Better Prognosis and Strong Cytotoxic Immune Response
- Author
-
de Nonneville, Alexandre, primary, Finetti, Pascal, additional, Picard, Maelle, additional, Monneur, Audrey, additional, Pantaleo, Maria Abbondanza, additional, Astolfi, Annalisa, additional, Ostrowski, Jerzy, additional, Birnbaum, Daniel, additional, Mamessier, Emilie, additional, and Bertucci, François, additional
- Published
- 2022
- Full Text
- View/download PDF
6. Neoadjuvant Chemotherapy for Breast Cancer: Evolution of Clinical Practice in a French Cancer Center Over 16 Years and Pathologic Response Rates According to Tumor Subtypes and Clinical Tumor Size: Retrospective Cohort Study
- Author
-
Houvenaeghel, Gilles, primary, de Nonneville, Alexandre, additional, Cohen, Monique, additional, Viret, Frédéric, additional, Rua, Sandrine, additional, Sabiani, Laura, additional, Buttarelli, Max, additional, Charaffe, Emmanuelle, additional, Monneur, Audrey, additional, Jalaguier-Coudray, Aurélie, additional, Bannier, Marie, additional, Sabatier, Renaud, additional, and Gonçalves, Anthony, additional
- Published
- 2022
- Full Text
- View/download PDF
7. 739P Efficacy and safety of maintenance olaparib and bevacizumab (bev) in ovarian cancer (OC) patients (pts) aged ≥65 years (y) from the PAOLA-1/ENGOT-ov25 first-line trial
- Author
-
Sabatier, Renaud, Vicier, Cécile, Garnier, Séverine, Guille, Arnaud, Carbuccia, Nadine, Isambert, Nicolas, Dalenc, Florence, Robert, Marie, Levy, Christelle, Pakradouni, Jihane, Adelaïde, José, Chaffanet, Max, Sfumato, Patrick, Mamessier, Emilie, Bertucci, François, Goncalves, Anthony, Mezni, Essia, Evans, Catherine Karine, Chinot, Olivier, Loschi, Alain, Arnaud, Sylvie, Mellinas, Marie, Bay, Jacques-Olivier, Bouleuc, Carole, Firmin, Nelly, Gandemer, Virginie, Magne, Nicolas, Orbach, Daniel, Penel, Nicolas, Rodrigues, Manuel, Thiery-Vuillemin, Antoine, Wislez, Marie, L’allemain, Gilles, Robert, Jacques, Colombo, Nicoletta, Dubot, Coraline, Lorusso, Domenica, Caceres, M. Valeria, Hasegawa, Kosei, Shapira-Frommer, Ronnie, Tewari, Krishnansu, Salman, Pamela, Hoyos Usta, Edwin, Yañez, Eduardo, Gümüş, Mahmut, Olivera Hurtado de Mendoza, Mivael, Samouëlian, Vanessa, Castonguay, Vincent, Arkhipov, Alexander, Toker, Sarper, Li, Kan, Keefe, Stephen, Monk, Bradley, Oaknin, Ana, Tinker, Anna, Gilbert, Lucy, Mathews, Cara, Brown, Jubilee, Barretina-Ginesta, Maria-Pilar, Moreno, Victor, Gravina, Adriano, Abdeddaim, Cyril, Banerjee, Susana, Guo, Wei, Danaee, Hadi, Im, Ellie, de Nonneville, Alexandre, Zemmour, Christophe, Frank, Sophie, Joly, Florence, Ray-Coquard, Isabelle, Costaz, Hèlène, Classe, Jean-Marc, Floquet, Anne, de La Motte Rouge, Thibault, Colombo, Pierre-Emmanuel, Sauterey, Baptiste, Leblanc, Eric, Pomel, Christophe, Marchal, Frédéric, Barranger, Emmanuel, Savoye, Aude-Marie, Guillemet, Cécile, Petit, Thierry, Pautier, Patricia, Rouzier, Roman, Gladieff, Laurence, Simon, Gaëtane, Courtinard, Coralie, Rousset-Rouviere, Sandrine, Rochigneux, Philippe, Chrétien, Anne-Sophie, Fattori, Stéphane, Gorvel, Laurent, Provansal, Magali, Lambaudie, Eric, Olive, Daniel, Martin, Johan, Guérin, Mathilde, Monneur, Audrey, Tassy, Louis, Tarpin, Carole, Extra, Jean-Marc, Viret, Frédéric, Pierga, Jean-Yves, Curé, Hervé, Abulnaja, Rakan, Bidard, François-Clément, Mari, Roxane, Narducci, Fabrice, Cappiello, Maria-Antonietta, Rousseau, Fréderique, Blache, Guillaume, Birnbaum, Daniel, Cropet, C., Montegut, C., Frindte, J., Cinieri, S., Guerra-Alia, E.M., Bogner, G., Yoshida, H., Vergote, I., Hietanen, S., Largillier, R., Canzler, U., Gratet, A., Marmé, F., Pujade-Lauraine, E., Favier, L., Ray-Coquard, I.L., Department of Medical Oncology, Institut Paoli-Calmettes, 232 Boulevard Sainte Marguerite, 13009 Marseille, France., Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Oncology ,medicine.medical_specialty ,Bevacizumab ,business.industry ,First line ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Hematology ,medicine.disease ,Olaparib ,chemistry.chemical_compound ,chemistry ,Internal medicine ,Medicine ,business ,Ovarian cancer ,medicine.drug - Abstract
International audience; 5548 Background: Ovarian cancer is the leading cause of death by gynecological cancer. Complete surgery remains one of the main prognostic factors. Laparoscopic exploration is mandatory to assess surgical resectability at diagnosis or after neoadjuvant chemotherapy. However, there is no clinical or biological marker that can correctly predict resectability and may be able to avoid a second laparoscopic exploration for initially unresectable diseases. Our aim was to assess circulating tumor DNA (ctDNA) value as a predictive non-invasive marker of evolution towards resectability for patients with epithelial ovarian cancer receiving first-line chemotherapy. Methods: We explored in this work one of the secondary objectives of the CIDOC study (NCT03302884). CIDOC is a multicenter prospective study aiming to explore ctDNA value as early marker of disease relapse after first-line treatment for epithelial ovarian cancer. Patients with mucinous histology or early stages not requiring chemotherapy are excluded. Plasma samples are collected at diagnosis, during neoadjuvant chemotherapy, and during follow-up. After DNA extraction, panel-based next generation sequencing is performed on both tumor samples and germline DNA, and somatic mutations of interest are selected for ctDNA monitoring. ctDNA analyses are conducted using droplet digital PCR (BioRad QX200) by measuring the variant allele fraction (VAF) of previously identified mutations. Results: This intermediary analysis has included 47 patients diagnosed between March 2017 and December 2019. Median age was 69 years old (48 – 84). Most of the patients had advanced disease (89.4% stage FIGO III or IV), serous histology (94.8%), and high grade tumor (92.3%). Most of the patients underwent complete interval cytoreductive surgery (76.3% vs 17.4% complete upfront surgery). Most of the tumors had TP53 mutations (85.1%), following by alterations involving DNA repair genes (38.3%). Median cell-free DNA concentration at baseline was 0.38 ng/µL (0 – 12.8). ctDNA was identified in 92.1% of patients at baseline with a median VAF of 1.84% (0 – 42.52%). ctDNA VAF was correlated to the peritoneal dissemination ( p= 0.039) assessed with the peritoneal cancer index. ctDNA clearance after preoperative chemotherapy tended to be correlated to achievement of complete interval surgery for patients receiving neoadjuvant chemotherapy ( p= 0.108). Conclusions: ctDNA may be a promising non-invasive marker to assess peritoneal cancer spreading and to predict surgical resectability after neoadjuvant chemotherapy. If confirmed in larger populations, this may enable to avoid additional surgical explorations for patients who remain ctDNA positive after chemotherapy. Clinical trial information: NCT03302884.
- Published
- 2021
8. PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic target
- Author
-
Bertucci, Francois, Finetti, Pascal, Monneur, Audrey, Perrot, Delphine, Chevreau, Christine, Le Cesne, Axel, Blay, Jean-Yves, Mir, Olivier, Birnbaum, Daniel, Blay, Jean‐yves, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Claudius Regaud, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy (IGR), Service d'Oncologie Médicale, Centre Léon Bérard [Lyon], Hôpital Cochin [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- Subjects
0301 basic medicine ,Genome instability ,Male ,Cancer Research ,DNA Repair ,[SDV]Life Sciences [q-bio] ,Poly (ADP-Ribose) Polymerase-1 ,0302 clinical medicine ,PARP1 ,Research Articles ,Aged, 80 and over ,Soft tissue sarcoma ,Sarcoma ,General Medicine ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,3. Good health ,PARP1 expression ,Gene Expression Regulation, Neoplastic ,Oncology ,030220 oncology & carcinogenesis ,soft tissue sarcoma ,PARP inhibitor ,Molecular Medicine ,Female ,Research Article ,Adult ,Adolescent ,DNA repair ,DNA damage ,Genomics ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,survival ,lcsh:RC254-282 ,03 medical and health sciences ,Young Adult ,Genetics ,medicine ,Humans ,Gene ,Aged ,Retrospective Studies ,business.industry ,medicine.disease ,Survival Analysis ,030104 developmental biology ,Cancer research ,prognosis ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
International audience; Soft tissue sarcomas (STSs) are aggressive tumors with few efficient systemic therapies. Poly(ADP-ribose) polymerase-1 (PARP1) inhibitors represent an emerging therapeutic option in tumors with genomic instability. The genomics of STSs is complex in more than half of cases, suggesting a high level of inherent DNA damage and genomic instability. Thus, STSs could be efficiently targeted with PARP inhibitors. Promising preclinical results have been reported, but few data are available regarding PARP1 expression in clinical samples. We examined PARP1 mRNA expression in 1464 clinical samples of STS, including 1432 primary tumors and 32 relapses, and searched for correlations with clinicopathological features, including metastasis-free survival (MFS). Expression was heterogeneous across the samples, not different between primary and secondary tumors, and was correlated to PARP1 DNA copy number. In the 1432 primary tumors, the 'PARP1-high' samples were associated with younger patients, more frequent locations at the extremities, superficial trunk and head and neck, more leiomyosarcomas and other STSs and less liposarcomas and myxofibrosarcomas, more grade 3, more high-risk CINSARC tumors, and more 'chromosomically instable' tumors. They were associated with shorter MFS, independently of other significant prognostic features, including the CINSARC signature. We found a strong involvement of genes overexpressed in the 'PARP1-high' samples in cell cycle, DNA replication, and DNA repair. PARP1 expression refines the prediction of MFS in STSs, and similar expression exists in secondary and primary tumors, supporting the development of PARP1 inhibitors.
- Published
- 2019
9. Additional file 1 of Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
- Author
-
Bertucci, François, Gonçalves, Anthony, Guille, Arnaud, Adelaïde, José, Garnier, Séverine, Carbuccia, Nadine, Billon, Emilien, Finetti, Pascal, Sfumato, Patrick, Monneur, Audrey, Pécheux, Christophe, Khran, Martin, Brunelle, Serge, Lenaïg Mescam, Thomassin-Piana, Jeanne, Poizat, Flora, Charafe-Jauffret, Emmanuelle, Turrini, Olivier, Lambaudie, Eric, Provansal, Magali, Jean-Marc Extra, Madroszyk, Anne, Gilabert, Marine, Sabatier, Renaud, Vicier, Cécile, Mamessier, Emilie, Chabannon, Christian, Pakradouni, Jihane, Viens, Patrice, André, Fabrice, Gravis, Gwenaelle, Popovici, Cornel, Birnbaum, Daniel, and Chaffanet, Max
- Abstract
Additional file 1. PERMED-01 protocol. The protocol of PERMED-01 trial.
- Published
- 2021
- Full Text
- View/download PDF
10. Additional file 4 of Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
- Author
-
Bertucci, François, Gonçalves, Anthony, Guille, Arnaud, Adelaïde, José, Garnier, Séverine, Carbuccia, Nadine, Billon, Emilien, Finetti, Pascal, Sfumato, Patrick, Monneur, Audrey, Pécheux, Christophe, Khran, Martin, Brunelle, Serge, Lenaïg Mescam, Thomassin-Piana, Jeanne, Poizat, Flora, Charafe-Jauffret, Emmanuelle, Turrini, Olivier, Lambaudie, Eric, Provansal, Magali, Jean-Marc Extra, Madroszyk, Anne, Gilabert, Marine, Sabatier, Renaud, Vicier, Cécile, Mamessier, Emilie, Chabannon, Christian, Pakradouni, Jihane, Viens, Patrice, André, Fabrice, Gravis, Gwenaelle, Popovici, Cornel, Birnbaum, Daniel, and Chaffanet, Max
- Abstract
Additional file 4: Supplementary Figures. Contains four Supplementary Figures showing the cancer types profiled and further NGA and aCGH results.
- Published
- 2021
- Full Text
- View/download PDF
11. Additional file 2 of Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial
- Author
-
Bertucci, François, Gonçalves, Anthony, Guille, Arnaud, Adelaïde, José, Garnier, Séverine, Carbuccia, Nadine, Billon, Emilien, Finetti, Pascal, Sfumato, Patrick, Monneur, Audrey, Pécheux, Christophe, Khran, Martin, Brunelle, Serge, Lenaïg Mescam, Thomassin-Piana, Jeanne, Poizat, Flora, Charafe-Jauffret, Emmanuelle, Turrini, Olivier, Lambaudie, Eric, Provansal, Magali, Jean-Marc Extra, Madroszyk, Anne, Gilabert, Marine, Sabatier, Renaud, Vicier, Cécile, Mamessier, Emilie, Chabannon, Christian, Pakradouni, Jihane, Viens, Patrice, André, Fabrice, Gravis, Gwenaelle, Popovici, Cornel, Birnbaum, Daniel, and Chaffanet, Max
- Abstract
Additional file 2: Supplementary methods. Contains additional methods regarding the trial design, the genome analyses, the molecular precision oncology report and molecular tumor board, and the statistical analyses.
- Published
- 2021
- Full Text
- View/download PDF
12. Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
- Author
-
Sabatier, Renaud, primary, Martin, Johan, additional, Vicier, Cécile, additional, Guérin, Mathilde, additional, Monneur, Audrey, additional, Provansal, Magali, additional, Tassy, Louis, additional, Tarpin, Carole, additional, Extra, Jean-Marc, additional, Viret, Frédéric, additional, and Goncalves, Anthony, additional
- Published
- 2021
- Full Text
- View/download PDF
13. [E-health and 'Cancer outside the hospital walls', Big Data and artificial intelligence]
- Author
-
Bertucci, Francois, Le Corroller-Soriano, Anne-Gaëlle, Monneur, Audrey, Fluzin, Sylvain, Viens, Patrice, Maraninchi, Dominique, Gonçalves, Anthony, Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U1252 INSERM - Aix Marseille Univ - UMR 259 IRD), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Direction du Système d’Information et de l’Organisation [IP-C, Marseille], Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Big Data ,Internet ,Ambulatoire ,Télémédecine ,Health Personnel ,[SDV]Life Sciences [q-bio] ,Information Seeking Behavior ,Aftercare ,Outpatient ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Digital ,[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM] ,Telemedicine ,Health Literacy ,Access to Information ,Numérique ,Artificial Intelligence ,Neoplasms ,Ambulatory Care ,e-santé ,Humans ,e-health ,Public Health ,Early Detection of Cancer ,Cancer - Abstract
International audience; To heal otherwise in oncology has become an imperative of Public Health and an economic imperative in France. Patients can therefore receive live most of their care outside of hospital with more ambulatory care. This ambulatory shift will benefit from the digital revolution and the development of digital health or e-health. Cancer research will also benefit with Big Data and artificial intelligence, which gather and analyze a huge amount of data. In this synthesis, we describe the different e-health tools and their potential impacts in oncology, at the levels of education and information of patients and caregivers, prevention, screening and diagnosis, treatment, follow-up, and research. A few randomized studies have already demonstrated clinical benefits. Large Big Data projects such as ConSoRe and Health Data Hub have been launched in France. We also discuss the issues and limitations of "cancer outside the hospital walls and e-health" from the point of view of patients, health care professionals, health facilities and government. This new organization will have to provide remote support "outside the walls" with care and follow-up of quality, continuous and prolonged in total safety and equity. Ongoing and future randomized clinical trials will need to definitively demonstrate areas of interest, advantages and drawbacks not only for patients, but also for caregivers, health facilities and governments.; Soigner autrement en Cancérologie est devenu un impératif de Santé Publique et un impératif économique en France. Aujourd’hui, les patients peuvent vivre l’essentiel de leurs soins hors des murs de l’hôpital avec une prise en charge de plus en plus ambulatoire. Ce virage ambulatoire va bénéficier de la révolution numérique et du développement de la santé numérique ou e-santé. La recherche va également en bénéficier avec le Big Data et l’intelligence artificielle qui collectent en réseau et analysent une masse de données considérable. Dans cette Synthèse, nous décrivons les différents outils d’e-santé et leurs impacts potentiels en Cancérologie aux niveaux de l’éducation et l’information des patients et soignants, la prévention, le dépistage et le diagnostic, le suivi sous traitement, la surveillance et la recherche. Quelques études randomisées ont déjà démontré le bénéfice clinique. Des gros projets de Big Data tels que ConSoRe et Health Data Hub ont été mis en place en France. Nous discutons les enjeux et les limites du « cancer hors les murs et e-santé » du point de vue des patients, des professionnels de la santé, des établissements de santé et des pouvoirs publics. Cette nouvelle organisation devra permettre un accompagnement à distance « hors des murs » assurant soins et suivi de qualité, continus et prolongés en toute sécurité et équité. Les essais cliniques randomisés en cours et futurs devront démontrer de manière définitive les domaines d’intérêt, les avantages et inconvénients non seulement pour les patients, mais également pour les soignants, les établissements de santé et les pouvoirs publics.
- Published
- 2020
14. LENVAGIST - A multicenter, comparative, placebo-controlled, double-blinded, phase II study of the efficacy of lenvatinib in patients with locally advanced or metastatic GIST after failure of imatinib and sunitinib.
- Author
-
Le Cesne, Axel, primary, Cropet, Claire, additional, Gautier, Julien, additional, Gagne, Stéphanie, additional, Francourt, Katia, additional, Remir, Emilie, additional, Hernandez, Caroline, additional, Dufresne, Armelle, additional, Ray-Coquard, Isabelle Laure, additional, Carbonnaux, Mélodie, additional, Mery, Benoite, additional, Vanacker, Helene, additional, Bertucci, Francois, additional, Launay, Simon, additional, Louvel-Perrot, Delphine, additional, Monneur, Audrey, additional, Brahmi, Mehdi, additional, and Blay, Jean-Yves, additional
- Published
- 2020
- Full Text
- View/download PDF
15. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers
- Author
-
Bertucci, François, primary, Rypens, Charlotte, additional, Finetti, Pascal, additional, Guille, Arnaud, additional, Adélaïde, José, additional, Monneur, Audrey, additional, Carbuccia, Nadine, additional, Garnier, Séverine, additional, Dirix, Piet, additional, Gonçalves, Anthony, additional, Vermeulen, Peter, additional, Debeb, Bisrat G., additional, Wang, Xiaoping, additional, Dirix, Luc, additional, Ueno, Naoto T., additional, Viens, Patrice, additional, Cristofanilli, Massimo, additional, Chaffanet, Max, additional, Birnbaum, Daniel, additional, and Van Laere, Steven, additional
- Published
- 2020
- Full Text
- View/download PDF
16. Quality of Life During Chemotherapy for Breast Cancer in a West African Population in Dakar, Senegal: A Prospective Study
- Author
-
Dano, Domitille, primary, Hénon, Clémence, additional, Sarr, Ousseynou, additional, Ka, Kanta, additional, Ba, Mouhamadou, additional, Badiane, Awa, additional, Thiam, Ibrahima, additional, Diene, Papa, additional, Diop, Mamadou, additional, Dem, Ahmadou, additional, Marino, Patricia, additional, Mancini, Julien, additional, Annede, Pierre, additional, Gonçalves, Anthony, additional, Diouf, Doudou, additional, and Monneur, Audrey, additional
- Published
- 2019
- Full Text
- View/download PDF
17. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors
- Author
-
Aoki, Shuichi, Inoue, Koetsu, Klein, Sebastian, Halvorsen, Stefan, Chen, Jiang, Matsui, Aya, Nikmaneshi, Mohammad, Kitahara, Shuji, Hato, Tai, Chen, Xianfeng, Kawakubo, Kazumichi, Nia, Hadi, Chen, Ivy, Schanne, Daniel, Shigeta, Kohei, Kikuchi, Hiroto, Ramjiawan, Rakesh, Schmidt, Tyge Ce, Iwasaki, Masaaki, Yau, Thomas, Hong, Theodore, Quaas, Alexander, Plum, Patrick, Dima, Simona, Popescu, Irinel, Bardeesy, Nabeel, Munn, Lance, Borad, Mitesh, Sassi, Slim, Jain, Rakesh, Zhu, Andrew, Duda, Dan, Guo, Yuchen, Gabola, Monica, Lattanzio, Rossano, Paul, Conception, Pinet, Valérie, Tang, Ruizhi, Turali, Hulya, Bremond, Julie, Longobardi, Ciro, Maurizy, Chloé, da Costa, Quentin, Finetti, Pascal, Boissière-Michot, Florence, Rivière, Benjamin, Lemmers, Céline, Garnier, Séverine, Bertucci, François, Zlobec, Inti, Chebli, Karim, Tazi, Jamal, Azar, Rania, Blanchard, Jean-Marie, Sicinski, Peter, Lemmers, Bénédicte, Hahne, Michael, Gonçalves, Anthony, Guille, Arnaud, Adelaïde, José, Carbuccia, Nadine, Billon, Emilien, Sfumato, Patrick, Monneur, Audrey, Pécheux, Christophe, Khran, Martin, Brunelle, Serge, Mescam, Lenaïg, Thomassin-Piana, Jeanne, Poizat, Flora, Charafe-Jauffret, Emmanuelle, Turrini, Olivier, Lambaudie, Eric, Provansal, Magali, Extra, Jean-Marc, Madroszyk, Anne, Gilabert, Marine, Sabatier, Renaud, Vicier, Cécile, Chabannon, Christian, Pakradouni, Jihane, Viens, Patrice, André, Fabrice, Gravis, Gwenaelle, Popovici, Cornel, Birnbaum, Daniel, Chaffanet, Max, Amoozgar, Zohreh, Kloepper, Jonas, Ren, Jun, Tay, Rong En, Kazer, Samuel, Kiner, Evgeny, Krishnan, Shanmugarajan, Posada, Jessica, Ghosh, Mitrajit, Wong, Christina, Ferraro, Gino, Batista, Ana, Wang, Nancy, Badeaux, Mark, Roberge, Sylvie, Xu, Lei, Huang, Peigen, Shalek, Alex, Fukumura, Dai, Kim, Hye-Jung, Shigeta, Ayako, Staiculescu, Daniel, Zopf, Dieter, Fiebig, Lukas, Hobbs, Gabriela, Cobbold, Mark, Goyal, Lipika, Birnbaum, David, Mamessier, Emilie, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Cancer Research ,Pancreatic ductal adenocarcinoma ,endocrine system diseases ,pancreatic cancer ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Biology ,lcsh:RC254-282 ,survival ,Article ,03 medical and health sciences ,0302 clinical medicine ,Downregulation and upregulation ,Pancreatic cancer ,Gene expression ,medicine ,Gene ,tumor location ,[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Phenotype ,digestive system diseases ,Gene expression profiling ,medicine.anatomical_structure ,Oncology ,expression profiling ,030220 oncology & carcinogenesis ,Cancer research ,030211 gastroenterology & hepatology ,prognosis ,Pancreas - Abstract
The association between pancreatic ductal adenocarcinoma (PDAC) location (head vs. Body/Tail (B/T)) and clinical outcome remains controversial. We collected clinicopathological and gene expression data from 249 resected PDAC samples from public data sets, and we compared data between 208 head and 41 B/T samples. The 2-year overall survival (OS) was better for the head than for the B/T PDACs (44 vs. 27%, p = 0.043), especially when comparing tumors with similar TNM classification (T3/4N0M0: 67% vs. 17%, p = 0.002) or from the same molecular class (squamous subtype: 31% vs. 0%, p <, 0.0001). Bailey&rsquo, s molecular subtypes were differentially distributed within the two groups, with the immunogenic subtype being underrepresented in the &ldquo, B/T&rdquo, group (p = 0.005). Uni- and multivariate analyses indicated that PDAC anatomic location was an independent prognostic factor. Finally, the supervised analysis identified 334 genes differentially expressed. Genes upregulated in the &ldquo, head&rdquo, group suggested lymphocyte activation and pancreas exocrine functions. Genes upregulated in the &ldquo, group were related to keratinocyte differentiation, in line with the enrichment for squamous phenotype. We identified a robust gene expression signature (GES) associated with B/T PDAC location, suggesting that head and B/T PDAC are different. This GES could serve as an indicator for differential therapeutic management based on PDAC location.
- Published
- 2019
18. PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
- Author
-
Monneur, Audrey, Goncalves, Anthony, Bertucci, Francois, Centre de Recherche en Cancérologie de Marseille (CRCM), Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Aix Marseille Université (AMU), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, and Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[SDV]Life Sciences [q-bio] - Abstract
The development of immune checkpoints inhibitors represents one of the major recent advances in oncology. Monoclonal antibodies directed against the programmed cell death protein 1 (PD-1) or its ligand (PD-L1) provides durable disease control, particularly in melanoma, lung, kidney, bladder and head and neck cancers. The purpose of this review is to synthesize current data on the expression of PD-L1 in breast cancer and on the preliminary clinical results of PD-1/PD-L1 inhibitors in breast cancer patients. In breast cancer, PD-L1 expression is heterogeneous and is generally associated with the presence of tumor-infiltrating lymphocytes as well as the presence of poor-prognosis factors, such as young age, high grade, ER-negativity, PR-negativity, and HER-2 overexpression, high proliferative index, and aggressive molecular subtypes (triple negative, basal-like, HER-2-overexpressing). Its prognostic value remains controversial when assessed with immunohistochemistry, whereas it seems favorable in triple-negative cancers when assessed at the mRNA level. Early clinical trials with PD-1/PD-L1 inhibitors in breast cancer have shown efficacy in terms of tumor response and/or disease control in refractory metastatic breast cancers, notably in the triple-negative subtype. Many trials are currently underway, both in the metastatic and neo-adjuvant setting. A crucial issue is identification of biomarkers predictive of response to PD-1/PD-L1 inhibitors.
- Published
- 2018
19. Successful Imatinib Treatment of an Abdominal Compartment Syndrome due to Huge Gastrointestinal Stromal Tumour
- Author
-
Bertucci, Alexandre, primary, Guiramand, Jérôme, additional, Mescam, Lena, additional, Monneur, Audrey, additional, Bisbal, Magali, additional, Chow-Chine, Laurent, additional, Sannini, Antoine, additional, Perrot, Delphine, additional, De Luca, Valéria, additional, Mokart, Djamel, additional, and Bertucci, François, additional
- Published
- 2019
- Full Text
- View/download PDF
20. Safety Results and Analysis of Eribulin Efficacy according to Previous Microtubules-Inhibitors Sensitivity in the French Prospective Expanded Access Program for Heavily Pre-treated Metastatic Breast Cancer
- Author
-
Sabatier, Renaud, primary, Diéras, Véronique, additional, Pivot, Xavier, additional, Brain, Etienne, additional, Roché, Henri, additional, Extra, Jean-Marc, additional, Monneur, Audrey, additional, Provansal, Magali, additional, Tarpin, Carole, additional, Bertucci, François, additional, Viens, Patrice, additional, Zemmour, Christophe, additional, and Gonçalves, Anthony, additional
- Published
- 2018
- Full Text
- View/download PDF
21. Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases
- Author
-
Monneur, Audrey, Monnier, Jilliana, Gaudy-Marqueste, Caroline, Devillier, Raynier, and Sabatier, Renaud
- Published
- 2017
- Full Text
- View/download PDF
22. Impact of Metastasis Surgery and Alkylating-Agent-Based Chemotherapy on Outcomes of Metastatic Malignant Phyllodes Tumors: A Multicenter Retrospective Study.
- Author
-
Neron, Mathias, Sajous, Christophe, Thezenas, Simon, Piperno-Neumann, Sophie, Reyal, Fabien, Laé, Marick, Chakiba, Camille, Penel, Nicolas, Ryckewaert, Thomas, Honoré, Charles, Bertucci, François, Monneur, Audrey, Salas, Sébastien, Duffaud, Florence, Saada-Bouzid, Esma, Isambert, Nicolas, Brahmi, Mehdi, Ray-Coquard, Isabelle, Blay, Jean-Yves, and Firmin, Nelly
- Abstract
Background: Metastatic phyllodes tumors have poor prognosis with median overall survival of 11.5 months. The objective of this study is to identify prognostic factors and the best options for management of metastatic malignant phyllode tumors (MMPTs). Patients and Methods: A multicentric retrospective study, including cases of MMPT from 10 sarcoma centers, was conducted. The primary end-point was overall survival (OS), and the secondary end-point was the clinical benefit of chemotherapy (CBCT) rate. Results: 51 MMPT patients were included. Median time from diagnosis to metastatic recurrence was 13 months. Management of MMPT consisted in surgery of the metastatic disease for 16 patients (31.3%), radiation therapy of the metastatic disease for 15 patients (31.9%), and chemotherapy for 37 patients (72.5%). Median follow-up was 62.1 months [95% confidence interval (CI) 31–80 months]. Median OS was 11.5 months (95% CI 7.5–18.7 months). On multivariate analysis, two or more metastatic sites [hazard ratio (HR) 2.81, 95% CI 1.27–6.19; p = 0.01] and surgery of metastasis (HR 0.33, 95% CI 0.14–0.78; p = 0.01) were independently associated with OS. The CBCT rate was 31.4% and 16.7% for the first and second lines. Polychemotherapy was not superior to single-agent therapy. Alkylating-agent-based chemotherapy, possibly associated with anthracyclines, was associated with a better CBCT rate than anthracyclines alone (p = 0.049). Conclusions: The results of this study emphasize the impact of the number of metastatic sites on survival of MMPT patients and the leading role of metastasis surgery in MMPT management. If systemic therapy is used, it should include alkylating agents, which are associated with a better clinical benefit. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. Giant Pedunculated Hepatic Hemangioma: A Case Report and Literature Review
- Author
-
Al Farai, Abdallah , primary, Mescam, Lénaïg, additional, De Luca, Valeria, additional, Monneur, Audrey, additional, Perrot, Delphine, additional, Guiramand, Jerome, additional, Delpero, Jean-Robert, additional, and Bertucci, François, additional
- Published
- 2018
- Full Text
- View/download PDF
24. Expression de PD-L1 et inhibiteurs de la voie PD-1/PD-L1 dans le cancer du sein
- Author
-
Monneur, Audrey, primary, Gonçalves, Anthony, additional, and Bertucci, François, additional
- Published
- 2018
- Full Text
- View/download PDF
25. Metastatic Intimal Sarcoma of the Pulmonary Artery Sensitive to Carboplatin-Vinorelbine Chemotherapy: Case Report and Literature Review
- Author
-
Cantaloube, Marie, primary, Moureau-Zabotto, Laurence, additional, Mescam, Lena, additional, Monneur, Audrey, additional, Deluca, Valeria, additional, Guiramand, Jerome, additional, Perrot, Delphine, additional, and Bertucci, François, additional
- Published
- 2018
- Full Text
- View/download PDF
26. Similar response profile to neoadjuvant chemotherapy, but different survival, in inflammatory versus locally advanced breast cancers
- Author
-
Monneur, Audrey, primary, Goncalves, Anthony, additional, Gilabert, Marine, additional, Finetti, Pascal, additional, Tarpin, Carole, additional, Zemmour, Christophe, additional, Extra, Jean-Marc, additional, Tallet, Agnès, additional, Lambaudie, Eric, additional, Jacquemier, Jocelyne, additional, Houvenaeghel, Gilles, additional, Boher, Jean-Marie, additional, Viens, Patrice, additional, and Bertucci, François, additional
- Published
- 2017
- Full Text
- View/download PDF
27. The use of systemic therapies to prevent progression of inflammatory breast cancer: which targeted therapies to add on cytotoxic combinations?
- Author
-
Gonçalves, Anthony, primary, Monneur, Audrey, additional, Viens, Patrice, additional, and Bertucci, François, additional
- Published
- 2017
- Full Text
- View/download PDF
28. Santé numérique et « cancer hors les murs », Big Dataet intelligence artificielle
- Author
-
Bertucci, François, Le Corroller-Soriano, Anne-Gaëlle, Monneur, Audrey, Fluzin, Sylvain, Viens, Patrice, Maraninchi, Dominique, and Goncalves, Anthony
- Abstract
Soigner autrement en Cancérologie est devenu un impératif de Santé Publique et un impératif économique en France. Aujourd’hui, les patients peuvent vivre l’essentiel de leurs soins hors des murs de l’hôpital avec une prise en charge de plus en plus ambulatoire. Ce virage ambulatoire va bénéficier de la révolution numérique et du développement de la santé numérique ou e-santé. La recherche va également en bénéficier avec le Big Dataet l’intelligence artificielle qui collectent en réseau et analysent une masse de données considérable. Dans cette Synthèse, nous décrivons les différents outils d’e-santé et leurs impacts potentiels en Cancérologie aux niveaux de l’éducation et l’information des patients et soignants, la prévention, le dépistage et le diagnostic, le suivi sous traitement, la surveillance et la recherche. Quelques études randomisées ont déjà démontré le bénéfice clinique. Des gros projets de Big Datatels que ConSoRe et Health Data Hubont été mis en place en France. Nous discutons les enjeux et les limites du « cancer hors les murs et e-santé » du point de vue des patients, des professionnels de la santé, des établissements de santé et des pouvoirs publics. Cette nouvelle organisation devra permettre un accompagnement à distance « hors des murs » assurant soins et suivi de qualité, continus et prolongés en toute sécurité et équité. Les essais cliniques randomisés en cours et futurs devront démontrer de manière définitive les domaines d’intérêt, les avantages et inconvénients non seulement pour les patients, mais également pour les soignants, les établissements de santé et les pouvoirs publics.
- Published
- 2020
- Full Text
- View/download PDF
29. Comparative genomic analysis of primary tumors and metastases in breast cancer
- Author
-
Bertucci, François, primary, Finetti, Pascal, additional, Guille, Arnaud, additional, Adélaïde, José, additional, Garnier, Séverine, additional, Carbuccia, Nadine, additional, Monneur, Audrey, additional, Charafe-Jauffret, Emmanuelle, additional, Goncalves, Anthony, additional, Viens, Patrice, additional, Birnbaum, Daniel, additional, and Chaffanet, Max, additional
- Published
- 2016
- Full Text
- View/download PDF
30. Telemonitoring program for genito-urinary cancer patients treated with oral anticancer agents.
- Author
-
Seguin, Lorene, Garcia, Melanie, Dulac, Morgane, Benizri, Frederic, Vicier, Cecile, Guerin, Mathilde, Muscat, Marie France, Monneur, Audrey, and Gravis, Gwenaelle
- Published
- 2023
- Full Text
- View/download PDF
31. Traitements systémiques des cancers du sein inflammatoires : un état des lieux
- Author
-
Monneur, Audrey, primary, Bertucci, François, additional, Viens, Patrice, additional, and Gonçalves, Anthony, additional
- Published
- 2014
- Full Text
- View/download PDF
32. Dramatic and Delayed Response to Doxorubicin-Dacarbazine Chemotherapy of a Giant Desmoid Tumor: Case Report and Literature Review
- Author
-
Monneur, Audrey, primary, Chetaille, Bruno, additional, Perrot, Delphine, additional, Guiramand, Jérôme, additional, and Bertucci, François, additional
- Published
- 2013
- Full Text
- View/download PDF
33. [E-health and "Cancer outside the hospital walls", Big Data and artificial intelligence].
- Author
-
Bertucci F, Le Corroller-Soriano AG, Monneur A, Fluzin S, Viens P, Maraninchi D, and Goncalves A
- Subjects
- Access to Information, Aftercare, Early Detection of Cancer, Health Personnel education, Humans, Information Seeking Behavior, Internet, Neoplasms diagnosis, Neoplasms prevention & control, Public Health, Telemedicine, Ambulatory Care, Artificial Intelligence, Big Data, Health Literacy, Neoplasms therapy
- Abstract
To heal otherwise in oncology has become an imperative of Public Health and an economic imperative in France. Patients can therefore receive live most of their care outside of hospital with more ambulatory care. This ambulatory shift will benefit from the digital revolution and the development of digital health or e-health. Cancer research will also benefit with Big Data and artificial intelligence, which gather and analyze a huge amount of data. In this synthesis, we describe the different e-health tools and their potential impacts in oncology, at the levels of education and information of patients and caregivers, prevention, screening and diagnosis, treatment, follow-up, and research. A few randomized studies have already demonstrated clinical benefits. Large Big Data projects such as ConSoRe and Health Data Hub have been launched in France. We also discuss the issues and limitations of "cancer outside the hospital walls and e-health" from the point of view of patients, health care professionals, health facilities and government. This new organization will have to provide remote support "outside the walls" with care and follow-up of quality, continuous and prolonged in total safety and equity. Ongoing and future randomized clinical trials will need to definitively demonstrate areas of interest, advantages and drawbacks not only for patients, but also for caregivers, health facilities and governments., (Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
34. [PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer].
- Author
-
Monneur A, Gonçalves A, and Bertucci F
- Subjects
- Antibodies, Monoclonal therapeutic use, Clinical Trials as Topic, Female, Humans, Lymphocytes, Tumor-Infiltrating, Neoplasm Proteins antagonists & inhibitors, Neoplasm Proteins metabolism, Prognosis, Programmed Cell Death 1 Receptor metabolism, Risk Factors, Triple Negative Breast Neoplasms metabolism, Triple Negative Breast Neoplasms therapy, B7-H1 Antigen antagonists & inhibitors, Breast Neoplasms metabolism, Breast Neoplasms therapy, Programmed Cell Death 1 Receptor antagonists & inhibitors
- Abstract
The development of immune checkpoints inhibitors represents one of the major recent advances in oncology. Monoclonal antibodies directed against the programmed cell death protein 1 (PD-1) or its ligand (PD-L1) provides durable disease control, particularly in melanoma, lung, kidney, bladder and head and neck cancers. The purpose of this review is to synthesize current data on the expression of PD-L1 in breast cancer and on the preliminary clinical results of PD-1/PD-L1 inhibitors in breast cancer patients. In breast cancer, PD-L1 expression is heterogeneous and is generally associated with the presence of tumor-infiltrating lymphocytes as well as the presence of poor-prognosis factors, such as young age, high grade, ER-negativity, PR-negativity, and HER-2 overexpression, high proliferative index, and aggressive molecular subtypes (triple negative, basal-like, HER-2-overexpressing). Its prognostic value remains controversial when assessed with immunohistochemistry, whereas it seems favorable in triple-negative cancers when assessed at the mRNA level. Early clinical trials with PD-1/PD-L1 inhibitors in breast cancer have shown efficacy in terms of tumor response and/or disease control in refractory metastatic breast cancers, notably in the triple-negative subtype. Many trials are currently underway, both in the metastatic and neo-adjuvant setting. A crucial issue is identification of biomarkers predictive of response to PD-1/PD-L1 inhibitors., (Copyright © 2018 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
35. [Systemic treatments of inflammatory breast cancer: an overview].
- Author
-
Monneur A, Bertucci F, Viens P, and Gonçalves A
- Subjects
- Anthracyclines therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Bevacizumab, Chemotherapy, Adjuvant methods, Clinical Trials, Phase II as Topic, Cyclophosphamide administration & dosage, Doxorubicin administration & dosage, Female, Fluorouracil administration & dosage, Humans, Inflammatory Breast Neoplasms mortality, Lapatinib, Neoadjuvant Therapy methods, Quinazolines therapeutic use, Trastuzumab, Angiogenesis Inhibitors therapeutic use, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Inflammatory Breast Neoplasms drug therapy, Molecular Targeted Therapy methods
- Abstract
The poor prognosis of inflammatory breast cancer (IBC) is due to its strong metastatic potential. During the last three decades, the introduction of neoadjuvant chemotherapy (CT), and its improvement with successive additions of anthracyclines and then taxanes, allowed to double the survival. However, the 5-year survival still remains lower than 50%, with the pathological complete response (pCR) to neoadjuvant CT being a major prognostic factor. Since 1995, several innovative approaches have been evaluated. Initially, the trials of high-dose CT with hematopoietic stem cell transplantation have generated promising results, but ultimately failed to change standards of treatment, in particular because of its toxicity. More recently, a few targeted therapies, combined to conventional CT, have been assessed, due to the frequent overexpression of HER2 and EGFR and the important vascularization of IBC. Trastuzumab, a monoclonal antibody targeting HER2, has shown a clear advantage in terms of pCR and survival in studies dedicated to, HER2-positive locally advanced breast cancers, including IBC. Lapatinib, a dual tyrosine kinase inhibitor anti-HER2 and EGFR, has shown significant activity in two phase II studies dedicated to HER2-positive IBC. The interest of HER2-double blockade by the combination of trastuzumab-pertuzumab combined to docetaxel has been demonstrated in term of pCR in the NEOSPHERE study which also included HER2-positive IBC. Among the anti-angiogenic drugs tested in studies dedicated to IBC, bevacizumab has given the most interesting results in term of efficacy/toxicity ratio. In the Beverly 2 study HER2-positive IBC patients were treated by the combination chemotherapy, trastuzumab and bevacizumab: the rate of pCR was 64%, and the 3-year disease-free and overall survivals were 68% and 90%, respectively; the increase of endothelial cells circulating was inversely correlated to the probability of pCR. All those treatments have been extrapolated from standard breast cancers. Thus, a deep molecular knowledge of IBC appears to be critical in order to develop specific treatments effectively targeting its particular aggressiveness.
- Published
- 2014
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.